Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.

Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I, Murphy B.

Head Neck. 2011 Dec;33(12):1804-8. doi: 10.1002/hed.21478.

2.

The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Mehra R, Cohen RB, Burtness BA.

Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50. Review.

3.

Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.

Raju U, Molkentine DP, Valdecanas DR, Deorukhkar A, Mason KA, Buchholz TA, Meyn RE, Ang KK, Skinner H.

Cancer Med. 2015 Jan;4(1):65-74. doi: 10.1002/cam4.345.

4.

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.

Le Tourneau C, Siu LL.

Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Review.

PMID:
18391623
5.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
6.

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY.

Mol Cancer Ther. 2011 Dec;10(12):2437-48. doi: 10.1158/1535-7163.MCT-11-0235.

7.

Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.

Bozec A, Peyrade F, Milano G.

Anticancer Agents Med Chem. 2013 Mar;13(3):389-402. Review.

PMID:
23092267
8.

Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Jiang N, Wang D, Hu Z, Shin HJ, Qian G, Rahman MA, Zhang H, Amin AR, Nannapaneni S, Wang X, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Ma J, Chen ZG, Saba NF.

Mol Cancer Ther. 2014 Jul;13(7):1826-36. doi: 10.1158/1535-7163.MCT-13-1093.

9.

Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.

Cheng H, Fertig EJ, Ozawa H, Hatakeyama H, Howard JD, Perez J, Considine M, Thakar M, Ranaweera R, Krigsfeld G, Chung CH.

Cancer Biol Ther. 2015;16(8):1252-8. doi: 10.1080/15384047.2015.1056418.

10.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.

Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.

Cancer Biol Ther. 2012 Aug;13(10):935-45. doi: 10.4161/cbt.20846.

11.

Cetuximab in squamous cell carcinoma of the head and neck.

Hitt R, Martín P, Hidalgo M.

Future Oncol. 2006 Aug;2(4):449-57. Review.

PMID:
16922611
12.

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH.

PLoS One. 2010 Sep 13;5(9):e12702. doi: 10.1371/journal.pone.0012702.

13.

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.

Herbst RS, Hong WK.

Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30. Review.

PMID:
12422310
14.

Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.

Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593.

15.

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.

Pogorzelski M, Ting S, Gauler TC, Breitenbuecher F, Vossebein I, Hoffarth S, Markowetz J, Lang S, Bergmann C, Brandau S, Jawad JA, Schmid KW, Schuler M, Kasper S.

Cell Death Dis. 2014 Feb 27;5:e1091. doi: 10.1038/cddis.2014.62.

16.

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O.

Eur J Cancer. 2013 Jul;49(10):2345-55. doi: 10.1016/j.ejca.2013.03.005.

PMID:
23578570
17.
18.

Cetuximab in squamous cell head and neck carcinomas.

Gebbia V, Giuliani F, Valori VM, Agueli R, Colucci G, Maiello E.

Ann Oncol. 2007 Jun;18 Suppl 6:vi5-7. Review.

PMID:
17591832
19.

Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.

Johansson AC, Ansell A, Jerhammar F, Lindh MB, Grénman R, Munck-Wikland E, Östman A, Roberg K.

Mol Cancer Res. 2012 Sep;10(9):1158-68.

20.
Items per page

Supplemental Content

Support Center